On the other hand, Tofacitinib inhibits JAK1, JAK2, JAK3 and is approved by the Food and Drug Administration (FDA) for treating rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis [33]. Here, JAK2 is linked to psoriatic arthritis.